Warhound Launches with US$ 200 mil. to Develop a Domestic Working-Dog Supply

United States, 22 October 2026 — Warhound, a new defence-technology company conceived by entrepreneurs Ben Lamm and Palmer Luckey, has emerged from stealth with US$200 million in seed funding to develop a domestic supply of working dogs for military, law-enforcement and emergency-response applications. The company named David Spirk as its chief executive officer.

Announced through a company-issued release on 22 October, the initiative combines canine biotechnology, biobanking, cloning, training and protective technologies. Warhound says it aims to reduce US dependence on overseas suppliers and improve the health, suitability and operational readiness of working dogs.

Colossal and Anduril form the technology backbone

Warhound says it will combine biotechnology licensed from Colossal Biosciences with Anduril’s protective equipment, software and situational-awareness technologies. The programme also includes training, animal care and plans for the long-term welfare of dogs throughout active service and retirement.

The company’s announcement lists investors including Sequoia Capital, In-Q-Tel, ARK Invest, Franklin Templeton, 8VC, Lux Capital and other investment firms and individuals. It also says the American Humane Society will guide welfare standards, certify training programmes and support retirement and reunification arrangements for retired working dogs.

A supply-chain problem drives the proposition

Warhound argues that the United States remains heavily reliant on European sources for military working dogs and that the acquisition and training pipeline is inefficient. Its release says more than 80% of US military working dogs are sourced from Europe and that fewer than half of procured dogs ultimately qualify for service after a demanding selection and training process. These are figures presented by the company, rather than an independently audited assessment included with the announcement.

The proposed model aims to combine selective breeding and advanced biotechnology with improved training and protective equipment. The company says it wants to produce dogs with better health and a higher likelihood of completing training, while improving the safety of dogs and handlers in operational settings.

Investment does not yet establish clinical or operational success

Warhound’s US$200 million seed round is confirmed by the company’s release. A valuation of US$1.2 billion and claims about genetically engineered dogs have appeared in secondary reporting, but those details are not disclosed in the company announcement reviewed for this article.

The company has not presented clinical evidence showing that its future dogs will have lower disease rates, better training outcomes or superior operational performance. Those remain development objectives.

Industry significance

Warhound represents an unusual convergence of animal biotechnology, defence technology and working-dog services. Its progress will be relevant to canine genetics, animal welfare, veterinary care, specialist breeding and the development of protective equipment for working animals.

The key milestones to watch include the company’s first programmes, independent evidence of animal-health outcomes, the welfare safeguards governing cloning and selection, and the demonstration of reliable supply at operational scale.